Myriad Genetics, Inc. (LON:0K3W)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 497.10M |
| Revenue (ttm) | 607.93M |
| Net Income (ttm) | -288.46M |
| Shares Out | n/a |
| EPS (ttm) | -3.16 |
| PE Ratio | n/a |
| Forward PE | 193.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,811 |
| Average Volume | 2,781 |
| Open | 7.64 |
| Previous Close | 7.49 |
| Day's Range | 7.41 - 7.75 |
| 52-Week Range | 3.76 - 28.75 |
| Beta | 1.78 |
| RSI | 71.14 |
| Earnings Date | Nov 4, 2025 |
About Myriad Genetics
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious o... [Read more]
Financial Performance
In 2024, Myriad Genetics's revenue was $837.60 million, an increase of 11.21% compared to the previous year's $753.20 million. Losses were -$127.30 million, -51.65% less than in 2023.
Financial numbers in USD Financial StatementsNews
ANGLE plc partners with Myriad Genetics to advance cancer diagnostics
Myriad Genetics announces CFO appointment
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been pro...
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing Cancer Risk Survey shows that more than ...
Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth
Myriad Genetics posted Q2 2025 revenue growth of 1% year-over-year, but adjusted for one-time events, growth would have been 5%. Key growth drivers include expanding Hereditary Cancer Testing to unaff...
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Shopify Inc. (NASDAQ: SHOP) rose sharply during Wednesday's session after the company reported bet...
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Shares of Astera Labs, Inc . (NASDAQ: ALAB) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter guidance above...
Myriad Genetics, Inc. 2025 Q2 - Results - Earnings Call Presentation
Myriad Genetics outlines high single-digit to low double-digit growth target through cancer care continuum focus
Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript
Myriad Genetics Surges 35.67% After Hours Following Strong Q2 Earnings Beat, Raised Revenue Guidance
Myriad Genetics Inc. (NASDAQ: MYGN) shares rallied 35.7%, to $5.25 in after-hours trading on Tuesday following second-quarter results that exceeded analyst expectations and raised full-year revenue g...
Myriad Genetics (MYGN) Q2 Revenue Up 6%
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
Myriad Genetics announced financial results for its second quarter ended June 30, 2025, updated full-year 2025 financial guidance on business performance.
Earnings Preview: Myriad Genetics
Myriad Genetics (NASDAQ: MYGN) is gearing up to announce its quarterly earnings on Tuesday, 2025-08-05. Here's a quick overview of what investors should know before the release. Analysts are estimati...
INVESTOR ALERT: Investigation of Myriad Genetics, Inc. (MYGN) Announced by Holzer & Holzer, LLC
ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) complied with federal securities laws...
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators Two Molecular Residual Disease (MRD) studies highlighting clini...
Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning p...
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "...
Ongoing Myriad Genetics, Inc. (MYGN) Investigation: Protect Your Rights - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning p...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "...
Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud
NEW YORK, NY / ACCESS Newswire / May 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning p...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "...
ATTENTION MYGN Shareholders: Lost Money on Myriad Genetics, Inc.? Contact Levi & Korsinsky About Investigation
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning p...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "...